1. Home
  2. TAP vs INSM Comparison

TAP vs INSM Comparison

Compare TAP & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Molson Coors Beverage Company Class B

TAP

Molson Coors Beverage Company Class B

HOLD

Current Price

$47.67

Market Cap

10.1B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$197.05

Market Cap

41.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TAP
INSM
Founded
1873
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1B
41.2B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
TAP
INSM
Price
$47.67
$197.05
Analyst Decision
Hold
Strong Buy
Analyst Count
15
19
Target Price
$51.47
$180.94
AVG Volume (30 Days)
4.0M
2.8M
Earning Date
11-04-2025
10-30-2025
Dividend Yield
3.94%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,214,000,000.00
$447,022,000.00
Revenue This Year
N/A
$43.10
Revenue Next Year
N/A
$128.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.34
52 Week Low
$42.94
$60.40
52 Week High
$64.66
$212.75

Technical Indicators

Market Signals
Indicator
TAP
INSM
Relative Strength Index (RSI) 58.10 51.97
Support Level $44.88 $189.59
Resistance Level $46.79 $206.69
Average True Range (ATR) 1.07 6.40
MACD 0.12 -2.76
Stochastic Oscillator 97.69 30.20

Price Performance

Historical Comparison
TAP
INSM

About TAP Molson Coors Beverage Company Class B

Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the US, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the US, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: